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ABSTRACT 
Background and Objectives: The development of contrast-induced nephropathy (CIN) is associated with an in-
creased risk of death and late cardiovascular events after percutaneous coronary intervention (PCI). The relation-
ship between CIN and hemoglobin drop has been controversial. The aim of this study was to evaluate the clinical 
usefulness of periprocedural hemoglobin drop as a nontraditional risk factor for CIN. Subjects and Methods: 
Five-hundred thirty-seven patients who underwent PCI were divided into 2 groups: Group I (486 patients: patients 
who did not develop CIN) and Group II (51 patients: patients who developed CIN). All patients were administered 
iodixanol as contrast media during coronary angiography. CIN is defined as a rise in serum creatinine of  ≥25% 
or  ≥0.5 mg/dL above the baseline value within 48 hours after contrast administration. Results: Baseline clinical 
and cardiovascular risk factors were not significantly different between the two groups, except for low abdominal 
circumference (Group I : Group II=87.9±9.0 cm : 81.2±15.1 cm, p=0.024), body weight (Group I : Group II= 
63.5±10.6 kg : 59.7±9.2 kg, p=0.008), body mass index (BMI) (Group I : Group II=24.4±3.4 kg/m
2 : 23.4±
2.8 kg/m
2, p=0.032), pre-PCI hemoglobin (Group I : Group II=13.2±2.0 g/dL : 12.3±2.0 g/dL, p=0.003), 
and post-PCI hemoglobin (Group I : Group II=12.4±1.9 g/dL : 11.5±1.8 g/dL, p=0.001). Multiple logistic re-
gression analysis showed that a periprocedural drop in hemoglobin (>1 g/dL) was an independent predictor of 
CIN, like other known risk factors. Conclusion: A periprocedural drop in hemoglobin of more than 1 g/dL is an-
other important independent predictor for CIN, even in patients administered the lowest nephrotoxic contrast 
agent, iodixanol, during PCI. (Korean Circ J 2010;40:68-73) 
 
KEY WORDS: Hemoglobin; Anemia; Contrast media; Renal insufficiency. 
 
 
Introduction 
 
Though percutaneous coronary intervention (PCI) is 
an effective treatment in the setting of coronary artery 
disease, contrast-induced nephropathy (CIN) is an im-
portant complication of iodinated contrast media in-
fused during diagnostic or interventional procedures.
1)2) 
CIN is the third leading cause of acute renal failure in 
admitted patients, accounting for 10% of all cases.
3) 
This iatrogenic complication has been a concern to the 
interventional cardiologists in recent years because of 
its adverse effect on prognosis. The development of CIN 
is associated with an increased risk of death and late 
cardiovascular events after PCI such as myocardial in-
farction and target vessel revascularization.
4-8) 
CIN is commonly defined as a rise in serum creati-
nine of ≥25% or ≥0.5 mg/dL above the baseline 
value within 48 hours after contrast administration. 
On the basis of this definition, the overall incidence of 
CIN in the general population is reported to be 1.2 to 
1.6%.
9-11)  
A key step in minimizing CIN is to identify patients 
at high risk. Known risk factors for CIN include chro-
nic kidney disease (CKD), diabetes mellitus (DM), vol- 
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ume depletion, nephrotoxic drug therapies, hemody-
namic instability, and intra-aortic balloon pump treat-
ment.
12-14) The additive nature of risk has allowed for 
the development of prognostic scoring systems, but the 
type and dose of contrast administration have not been 
fully analyzed in these scoring systems.
15)16) Moreover, 
the American College of Cardiology/American Heart 
Association (ACC/AHA) guidelines for acute coronary 
syndromes in the setting of CKD list the use of isosmo-
lal contrast media as a class I (Level A) recommenda-
tion.
17) However, isosmolal contrast media is not admi-
nistered for all patients in routine clinical practice, which 
creates discrepancies between the scoring systems and 
daily practice. To avoid such discrepancies, we investi-
gated other possible risk factors for CIN in PCI patients 
who were administered an isosmolal contrast agent, io-
dixanol, as the only contrast media.   
 
Subjects and Methods 
 
In order to minimize the potential role of hemody-
namic instability as a cause of postprocedural renal fail-
ure, patients were excluded who had ST-segment ele-
vation myocardial infarction requiring primary PCI, or 
cardiogenic shock requiring treatment with an intra-
aortic balloon pump (IABP) or inotropic agents. Patients 
with serum creatinine >4.0 mg/dL, dependence on dia-
lysis, neoplasms, vascular malformations, thrombocy-
topenia, or major bleeding (intracranial, intraocular, or 
retroperitoneal hemorrhage, clinical bleeding with he-
moglobin drop >3.0 g/dL, or red cell transfusion  ≥2 
units) were also excluded. For patients who underwent 
more than one angiographic procedure during the st-
udy period, only the first PCI was included.   
There were 956 patients who underwent PCI at Ch-
onbuk National University Hospital between January 
2005 and December 2006. Of these, we excluded 23 pa-
tients who had definite cause for renal dysfunction after 
PCI such as infection, renal artery thrombosis, hemoly-
sis, rhabdomyolysis, renal stone, or prostate disease. We 
retrospectively analyzed the medical records of 537 pa-
tients who underwent PCI and were administered io-
dixanol (Visipaque
®, GE Health Care, Cork, Ireland) 
as contrast media. The patients were divided into two 
groups: Group I (486 patients who did not develop CIN) 
and Group II (51 patients who developed CIN). 
Elective PCI patients received routine hydration with 
0.9% normal saline >1 mL/kg/hour from 4 to 12 hours 
before PCI and continuing after PCI. However, some 
patients requiring urgent PCI could not receive suffi-
cient hydration {79 (16.3%) in Group I vs. 10 (19.6%) 
in Group II}. N-acetylcysteine 600 mg was admini-
stered twice on the day before the procedure and twice 
on the day after the procedure.   
CIN was defined as a postprocedural increase in se-
rum creatinine of  ≥0.5 mg/dL or an increase of 25% 
from baseline. Absolute or relative increase in serum 
creatinine at 24 hours or 48 hours were compared to 
baseline serum creatinine, and CIN was diagnosed when 
alternative explanations for aggravation of renal dys-
function were ruled out. Per study design, blood sam-
ples were drawn before PCI and 24 hours after PCI to 
measure serum creatinine; further determinations of cre-
atinine beyond 24 hours were done if clinically indicated. 
Diagnostic angiography and PCI were performed 
after premedication with aspirin (at least 100 mg) and 
unfractionated or low molecular weight heparin. A load-
ing dose of clopidogrel (between 300 mg and 600 mg) 
was administered before PCI. Coronary angiography was 
performed through the femoral or radial artery. Hepa-
rin was infused throughout the procedure to maintain 
an activated clotting time of 250 seconds or longer. St-
ents were deployed after prior balloon angioplasty, and 
administration of a platelet glycoprotein IIb/IIIa-recep-
tor blocker was left to the decision of the surgeon. The 
appropriate length and diameter coronary stent was care-
fully selected to properly cover the target lesion. Each 
individual physician decided on selection of the trans-
radial or transfemoral approach, contrast dose, inter-
ventional technique, supportive pharmacologic thera-
pies, and post-dilatation with a non-compliant high-
pressure balloon. Therapeutic decision-making and the 
need for interventional therapy in patients with unstable 
angina/non-ST-elevation myocardial infarction (NSTE-
MI) were left to the physician’s choice according to the 
guidelines of the ACC/AHA/Society for Cardiovascu-
lar Angiography and Interventions (SCAI).
18)19) 
The baseline clinical characteristics, laboratory char-
acteristics, and coronary angiography findings {includ-
ing ACC/AHA classification, and Thrombolysis In Myo-
cardial Infarction (TIMI) flow grade before and after 
PCI} were analyzed for groups I and II. To examine a 
report that each 3% periprocedural drop in hematocrit 
(known to correspond approximately to 1 g/dL of he-
moglobin) resulted in development of CIN, we also 
analyzed the effect of a decrease in hemoglobin by ≤
1 g/dL, 1-2 g/dL, ≥2 g/dL on the development of CIN 
in our study population.
20)  
For continuous variables, comparisons between the 
groups were done using Student’s t-test. Fischer’s exact 
test was used to evaluate the categorical variables. To 
test whether initial differences between the two groups 
influenced the differing results, multiple logistic regres-
sion analysis was performed after controlling the vari-
ables that were significantly different at baseline. All 
continuous variables are described as mean±standard 
deviation. All analyses were 2-tailed, with clinical sig-
nificance defined as p<0.05. All statistical processing 
was done using SPSS-PC 15.0 (Statistical Package for the 
Social Sciences, SPSS-PC. Inc., Chicago, IL, USA).  
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Results 
 
Baseline clinical and laboratory characteristics (Table 
1) were not significantly different between the two gr-
oups. However, patients who developed CIN (Group II) 
had lower abdominal circumference, body weight, body 
mass index (BMI), baseline hemoglobin, and post-PCI 
hemoglobin levels.   
There was no significant difference between the two 
groups with regard to lesion characteristics by coronary 
angiography according to ACC/AHA classification or 
TIMI flow grade before PCI. Moreover, the drugs used 
for anticoagulation and the closure device were not dif-
ferent between the two groups. However, the TIMI flow 
grade after PCI was higher in patients who did not de-
velop CIN (Group I) compared to the patients who 
developed CIN (Group II) (3.0±0.2 vs. 2.8±0.4, p= 
0.003) (Table 2). Indications for PCI were different bet-
ween the two groups. The proportion of urgent PCIs 
(early invasive PCI rather than elective PCI) was higher 
in Group II (45.1%) than in Group I (35.2%) (p=0.009). 
The proportion of patients who experienced a drop 
in hemoglobin of more than 1 g/dL was higher among 
patients who developed CIN (Group II, 54.9%) com-
pared with patients who did not develop CIN (Group 
I, 39.3%) (p=0.036) (Fig. 1).  
Multivariate logistic regression analysis was done both 
by statistically significant variables (body weight, base-
line hemoglobin, post-PCI hemoglobin, pre-PCI Cr, 
post-PCI Cr, and TIMI flow grade after PCI) and con-
ventional risk factors for CIN (age, anemia, and urgent 
PCI). Multivariate logistic regression analysis showed 
that the strong predictors for the development of CIN 
(Table 3) were consistent with previous studies; age, 
body weight, anemia, pre-PCI creatinine, and urgent 
PCI. Like other known risk factors for CIN, a decrease 
in hemoglobin by >1 g/dL was a strong predictor for 
the development of CIN {adjusted odds ratio (aOR)= 
2.238, p=0.012}. 
 
Discussion 
 
CIN is one of the most common causes of acute 
renal failure in hospitalized patients. The frequency of 
Table 1. Baseline clinical characteristics 
  Group I (n=486)  Group II (n=51)  p
Age (years)  62.0±11.5 64.6±10.3 0.093
Male (%)  310 (63.8)  29 (56.9)  0.361
Risk factor (%)       
Hypertension  244 (50.2)  26 (51.0)  1.000
Diabetes mellitus  138 (28.4)  15 (29.4)  0.871
Hyperlipidemia  95 (19.5)  7 (13.7)  0.355
Smoking  216 (44.4)  22 (43.1)  0.752
Diagnosis (%)       
STEMI  87 (17.9)  10 (19.6)  0.431
NSTEMI  91 (18.7)  10 (19.6)  0.542
UAP  184 (37.9)  18 (35.3)  0.754
SAP  124 (25.5)  13 (25.5)  0.346
Abdominal circumference (cm)  87.7±9.0 81.2±15.1 0.024
Body weight (kg)  63.5±10.6 59.7±9.2 0.008
BMI (kg/m
2) 24.4±3.4 23.4±2.8 0.032
Lab findings       
Baseline hemoglobin (g/dL)  13.2±2.0 12.3±2.0 0.003
Post-PCI hemoglobin (g/dL)  12.4±1.9 11.5±1.8 0.001
Serum uric acid (mg/dL)  5.8±4.1 6.2±3.1 0.464
Pre-PCI Cr (mg/dL)  1.03±0.41 1.41±0.43 0.001
Post-PCI Cr (mg/dL)  0.94±0.38 2.00±0.41 0.001
Total cholesterol (mg/dL)  179.9±41.3 168.0±49.4 0.133
Triglyceride (mg/dL)  137.4±96.7 134.7±59.2 0.554
HDL-C (mg/dL)  41.1±11.8 39.8±9.2 0.087
LDL-C (mg/dL)  120.1±41.8 126.5±43.0 0.212
LVEF (%)  55.3±9.9 51.8±11.1 0.057
STEMI: ST-elevation-myocardial infarction, NSTEMI: non-ST elevation myocardial infarction, UAP: unstable angina pectoris, SAP: stable 
angina pectoris, BMI: body mass index, PCI: percutaneous coronary intervention, HDL-C: high-density lipoprotein-cholesterol, LDL-C:
low-density lipoprotein-cholesterol, LVEF: left ventricular ejection fraction 
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CIN has decreased over the past decade from a general 
incidence of -15% to -7%.
15) CIN is associated with 
prolonged in-hospital stay and increased morbidity, 
mortality, and cost. In the Mayo Clinic registry, the in-
hospital death rate was 22% among the patients who 
developed CIN compared to only 1.4% in patients who 
did not develop CIN. Among hospital survivors with 
CIN, 1- and 5-year estimated mortality rates were 12.1% 
and 44.6%, respectively, much greater than the 3.7% 
and 14.5% mortality rates noted in patients without 
CIN (p<0.0001).
1)  
Although the pathogenesis of CIN is not completely 
known, multiple mechanisms may be involved. Gener-
ally, the pathophysiology of CIN assumes baseline re-
duced nephron number, with superimposed acute va-
soconstriction caused by the release of adenosine, en-
dothelin, and other renal vasoconstrictors triggered by 
iodinated contrast. After a very brief increase in renal 
blood flow, there is an overall -50% sustained reduc-
tion in renal blood flow lasting for several hours. Pro-
longed contrast transit time in the kidney increases the 
exposure of renal tubular cells to contrast. This stasis 
of contrast in the kidney allows for direct cellular in-
jury and death in renal tubular cells. Furthermore, the 
sustained reduction in renal blood flow to the outer 
medulla leads to medullary hypoxia, ischemic injury, 
and death of renal tubular cells.
21) 
Many individual risk factors have been reported in 
relation to the development of CIN. The best recogniz-
ed non-modifiable risk factors are older age, DM, pre-
existent renal insufficiency, congestive heart failure, he-
modynamic instability, and nephritic syndrome. Modi-
fiable risk factors include volume depletion, volume of 
contrast media, nephrotoxic drug use, low serum albu-
min level (<35 g/L), and anemia.
22)23)  
Dangas et al.
24) showed that the baseline hematocrit 
level is an independent predictor of CIN in patients 
with CKD (OR=0.95, p<0.00001). Nikolsky et al.
20) re-
ported that lower baseline hematocrit was an indepen-
dent predictor for CIN in 6,773 consecutive patients tr-
eated with PCI. Moreover, the CIN rate steadily increas-
ed with baseline hematocrit quintile decrements (from 
10.3% in the highest quintile to 23.3% in the lowest qu-
intile) (p<0.0001). Each 3% drop in hematocrit (known 
to correspond to approximately 1 g/dL of hemoglobin) 
resulted in a 30% increase in the risk of CIN (p<0.0001) 
in patients with baseline CKD and a 26% increase in 
the risk of CIN in patients without CKD (p<0.0001). 
On multiple logistic regression analysis in the present 
study, traditional risk factors for CIN such as age, body 
weight, anemia, pre-PCI creatinine, and urgent PCI 
showed a significant association with CIN, consistent 
with previous studies. Interestingly, the present study 
indicates that a hemoglobin drop (>1 g/dL) during 
PCI is an important predicting factor for CIN, just like 
other known risk factors. Even though the association 
between hemoglobin drop and higher rates of CIN is 
not clearly understood, patients with a greater decrease 
in hemoglobin were older, had lower baseline hemo-
Table 3. Multiple logistic regression analysis 
  aOR  95% CI  p
Age 1.560  1.151-1.980 0.007
Body weight (kg)  0.919  0.880-0.958 0.001
Anemia 1.554  1.145-1.972 0.042
Hemoglobin drop >1 g/dL  2.238  1.190-4.209 0.012
Pre-PCI Cr  4.672  2.393-9.121 0.001
Urgent PCI  2.688  1.425-5.072 0.002
PCI: percutaneous coronary intervention, aOR: adjusted odds 
ratio, CI: confidence interval 
Table 2. Angiographic and anticoagulation characteristics
  Group I   
(n=486) 
Group II 
(n=51)  p
ACC/AHA 
 classification  (%)      
A  33 (6.8)  3 (5.9)  1.000
B1  149 (30.7)  17 (33.3)  0.463
B2  156 (32.0)  15 (29.4)  0.698
C  148 (30.5)  16 (31.4)  0.126
B2 or C  354 (62.5)  39 (60.8)  0.244
TIMI flow grade       
Before PCI  2.1±1.2 1.5±1.6 0.230
After PCI  3.0±0.2 2.8±0.4 0.003
Urgent PCI (%)  171 (35.2)  23 (45.1)  0.009
Volume of 
 contrast  media  213.4±132.8 223.1±153.4 0.137
Drug administration (%)       
Abciximab  46 (9.5)  12 (23.5)  0.088
LMWH  248 (51.0)  32 (62.7)  0.318
Heparin 385  (79.2)  44  (86.3)  0.274
Closure device (%)  155 (31.9)  14 (27.5)  0.635
ACC/AHA: American College of Cardiology/American Heart As-
sociation, TIMI: Thrombolysis In Myocardial Infarction, PCI: per-
cutaneous coronary intervention, LMWH: low molecular weight
heparin 
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Fig. 1. There was a significant difference in the proportion of pa-
tients with a drop in hemoglobin (>1 g/dL). There was higher pro-
portion of patients with an drop in hemoglobin among patients
who developed CIN. CIN: contrast-induced nephropathy. 
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globin, and required more urgent PCI.
16)25) Periproce-
dural hemoglobin drop was likely related to blood loss 
incurred through puncture site hematoma formation, 
and through catheter aspiration. Those had an additive 
impact to the prevention of CIN in real clinical practice. 
In the present study, all patients were administered 
the lowest nephrotoxic isosmolal contrast agent and 
there was no statistical difference in administered con-
trast agent volume. The clinical meaning of the present 
study is that physician should make every effort to de-
crease periprocedural bleeding, even in a setting of 
lowest nephrotoxic contrast agent and N-acetylcysteine 
prevention. 
However, our small, single tertiary center, retrospec-
tive study has several limitations. First, we may have un-
derestimated the incidence of CIN because we did not 
check routine serum creatinine at 72 hours after PCI. 
Moreover, routine hydration could not be carried out 
in some patients who required urgent PCI within 4 
hours. These discrepancies should be considered in fu-
ture investigations. Second, our study did not address 
the other important variables related to CIN, such as 
hydration volume, urine output, hemodynamic para-
meters, procedure time and nephrotoxic medications. 
This is major limitation of our study. Third, our study 
was directed at low risk patients. We excluded patients 
who were at high risk for CIN, such as those with serum 
creatinine >4.0 g/dL, primary PCI, cardiogenic shock 
and major bleeding. Fourth, we did not analyze all red 
blood cell data on erythropoietin levels, plasma vol-
ume, and red blood cell mass that would provide more 
information on the development of CIN.   
In summary, a periprocedural drop in hemoglobin 
of more than 1 g/dL is another important indepen-
dent predictor for CIN, even in patients administered 
the lowest nephrotoxic contrast agent, iodixanol, dur-
ing PCI. Because even a small amount of procedure-
related blood loss is associated with the development 
of CIN and leads to poorer clinical outcomes, inter-
ventional cardiologists should maker every effort to re-
duce blood loss during PCI.   
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